As Director, Nonclinical, and Early clinical development, Carlo is responsible for leading projects for which strategic considerations are particularly challenging. Since joining VCLS, he has worked on approximately 700 major life-science projects, including gap analyses, project development plans, investigator brochures, CTD Modules (2.4, 2.6), and packages for scientific advice and investigational new drug meetings with the EMA and FDA, respectively.
He brings to the role more than 25 years of experience in the drug development process, having worked with new chemical entities, well-established products, combination products, biologics, biosimilars and gene therapy medicinal products across a range of therapeutic areas, including oncology, autoimmune disorders, CNS disorders, ophthalmology, respiratory disease, inflammation, muscular dystrophies, dermatology, vaccines, pain, stroke, and (cardio)vascular disorders.
Prior to joining VCLS, Carlo headed-up clinical development at Med Discovery, a Swiss biopharmaceutical company dedicated to the discovery and development of highly specific treatments for urogenital cancers. Whilst there, Carlo had specific responsibility for evaluating and selecting clinical CROs and vendors, writing development plans, and major clinical documents as well as organizing scientific and clinical advisory boards with key opinion leaders in oncology.
Carlo started his career in Geneva working for the American CRO Battelle as a research scientist. He subsequently moved to OM Pharma, a Swiss pharmaceutical company now part of the Vifor Pharma, where he was initially employed as a pharmacologist, before being promoted to Head of nonclinical development and phase I and II studies. During this time, Carlo gained significant experience in immunotherapy, vaccine development, immunology, autoimmune diseases (such as rheumatoid arthritis, lupus, and multiple sclerosis) and oncology.
Carlo is based in the VCLS Swiss offices in Lausanne, Switzerland.
